Disease on EC 1.14.13.9 - kynurenine 3-monooxygenase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acquired Immunodeficiency Syndrome
Tryptophan metabolism in relation to amino acid alterations during typhoid fever.
Alzheimer Disease
A fluorescence polarization binding assay to identify inhibitors of flavin-dependent monooxygenases.
Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway.
Development of a Rapid Fluorescence-Based High-Throughput Screening Assay to Identify Novel Kynurenine 3-Monooxygenase Inhibitor Scaffolds.
Metabolism and Pharmacokinetics of JM6 in Mice: JM6 is Not a Prodrug for Ro-61-8048.
Prognostic significance of kynurenine 3-monooxygenase and effects on proliferation, migration, and invasion of human hepatocellular carcinoma.
Structural basis of kynurenine 3-monooxygenase inhibition.
Substrate and inhibitor specificity of kynurenine monooxygenase from Cytophaga hutchinsonii.
Astrocytoma
Central Nervous System Infection with Borna Disease Virus Causes Kynurenine Pathway Dysregulation and Neurotoxic Quinolinic Acid Production.
Brain Edema
Modification of kynurenine pathway via inhibition of kynurenine hydroxylase attenuates surgical brain injury complications in a male rat model.
[Effects of Cinnabar and Realgar in Angong Niuhuang powder on heat shock protein, nitric oxide synthase and inflammatory cytokines in contusion cerebral edema]
[Effects of cinnabar and realgar in angong niuhuang powder on lactate dehydrogenase and its isoenzymes in rats with infectious cerebral edema]
Brain Injuries
Modification of kynurenine pathway via inhibition of kynurenine hydroxylase attenuates surgical brain injury complications in a male rat model.
Realgar and cinnabar are essential components contributing to neuroprotection of Angong Niuhuang Wan with no hepatorenal toxicity in transient ischemic brain injury.
Brain Ischemia
Kynurenine 3-hydroxylase in brain: species activity differences and effect of gerbil cerebral ischemia.
Kynurenine hydroxylase inhibitors reduce ischemic brain damage: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol-2yl]-benzenesulfonamide (Ro 61-8048) in models of focal or global brain ischemia.
[Absorption and distribution of mercury and arsenic from realgar and cinnabar of angong niuhuang pill in normal rats and rats with cerebral ischemia]
Breast Neoplasms
Kynurenine 3-monooxygenase upregulates pluripotent genes through ?-catenin and promotes triple-negative breast cancer progression.
Carcinogenesis
Kynurenine 3-monooxygenase (KMO), and signal transducer and activator of transcription 3 (STAT3) expression is involved in tumour proliferation and predicts poor survival in canine melanoma.
Kynurenine 3-monooxygenase upregulates pluripotent genes through ?-catenin and promotes triple-negative breast cancer progression.
Carcinoma, Hepatocellular
Kynurenine 3-monooxygenase (KMO), and signal transducer and activator of transcription 3 (STAT3) expression is involved in tumour proliferation and predicts poor survival in canine melanoma.
Prognostic significance of kynurenine 3-monooxygenase and effects on proliferation, migration, and invasion of human hepatocellular carcinoma.
Central Nervous System Neoplasms
Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).
Chorea
The kynurenine 3-hydroxylase inhibitor Ro 61-8048 improves dystonia in a genetic model of paroxysmal dyskinesia.
Cluster Headache
The Role of the Kynurenine Signaling Pathway in Different Chronic Pain Conditions and Potential Use of Therapeutic Agents.
Colitis
Kynurenine plays an immunosuppressive role in 2,4,6-trinitrobenzene sulfate-induced colitis in mice.
Dyskinesias
Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: Common implication of striatal neuropeptides.
Effects of the kynurenine 3-hydroxylase inhibitor Ro 61-8048 after intrastriatal injections on the severity of dystonia in the dt sz mutant.
Implication of NMDA Receptors in the Antidyskinetic Activity of Cabergoline, CI-1041, and Ro 61-8048 in MPTP Monkeys with Levodopa-induced Dyskinesias.
Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys.
The kynurenine 3-hydroxylase inhibitor Ro 61-8048 improves dystonia in a genetic model of paroxysmal dyskinesia.
Dystonia
Effects of the kynurenine 3-hydroxylase inhibitor Ro 61-8048 after intrastriatal injections on the severity of dystonia in the dt sz mutant.
The kynurenine 3-hydroxylase inhibitor Ro 61-8048 improves dystonia in a genetic model of paroxysmal dyskinesia.
Encephalomyelitis, Autoimmune, Experimental
Kynurenine pathway modulation reverses the experimental autoimmune encephalomyelitis mouse disease progression.
Gastritis
Kynurenine 3-monooxygenase mediates inhibition of Th17 differentiation via catabolism of endogenous aryl hydrocarbon receptor ligands.
Glioma
Involvement of the kynurenine pathway in human glioma pathophysiology.
Hearing Loss
Ototoxicity induced by cinnabar (a naturally occurring HgS) in mice through oxidative stress and down-regulated Na(+)/K(+)-ATPase activities.
Huntington Disease
A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease.
Assessing and Modulating Kynurenine Pathway Dynamics in Huntington's Disease: Focus on Kynurenine 3-Monooxygenase.
Bacterial expression of human kynurenine 3-monooxygenase: solubility, activity, purification.
Development of a Rapid Fluorescence-Based High-Throughput Screening Assay to Identify Novel Kynurenine 3-Monooxygenase Inhibitor Scaffolds.
Development of a Series of Aryl Pyrimidine Kynurenine Monooxygenase Inhibitors as Potential Therapeutic Agents for the Treatment of Huntington's Disease.
Development of a Series of Kynurenine 3-Monooxygenase Inhibitors Leading to a Clinical Candidate for the Treatment of Acute Pancreatitis.
Development of LC/MS/MS, High-Throughput Enzymatic and Cellular Assays for the Characterization of Compounds That Inhibit Kynurenine Monooxygenase (KMO).
First molecular modeling report on novel arylpyrimidine kynurenine monooxygenase inhibitors through multi-QSAR analysis against Huntington's disease: A proposal to chemists!
Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).
Targeting Kynurenine 3-Monooxygenase (KMO): Implications for Therapy in Huntington's Disease.
The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease.
Hyperalgesia
Upregulation of neuronal kynurenine 3-monooxygenase mediates depression-like behavior in a mouse model of neuropathic pain.
Hyperpigmentation
An Improved Nanoemulsion Formulation Containing Kojic Monooleate: Optimization, Characterization and In Vitro Studies.
Hypersensitivity
Allergic reactions to tattoo pigment after laser treatment.
Pharmacological Inhibition of Indoleamine 2,3-Dioxygenase-2 and Kynurenine 3-Monooxygenase, Enzymes of the Kynurenine Pathway, Significantly Diminishes Neuropathic Pain in a Rat Model.
[Analysis of adverse effects of cinnabar]
Hypotension
Vasorelaxing Action of the Kynurenine Metabolite, Xanthurenic Acid: The Missing Link in Endotoxin-Induced Hypotension?
Hypothyroidism
Presence of kynurenine hydroxylase in developing rat brain.
Infarction, Middle Cerebral Artery
Kynurenine hydroxylase inhibitors reduce ischemic brain damage: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol-2yl]-benzenesulfonamide (Ro 61-8048) in models of focal or global brain ischemia.
Infections
A fluorescence polarization binding assay to identify inhibitors of flavin-dependent monooxygenases.
Antiviral Effect of IDO in Mouse Fibroblast Cells During Influenza Virus Infection.
Central Nervous System Infection with Borna Disease Virus Causes Kynurenine Pathway Dysregulation and Neurotoxic Quinolinic Acid Production.
Kynurenine 3-Monooxygenase Inhibition during Acute Simian Immunodeficiency Virus Infection Lowers PD-1 Expression and Improves Post-Combination Antiretroviral Therapy CD4+ T Cell Counts and Body Weight.
Ischemic Attack, Transient
Mechanism of delayed increases in kynurenine pathway metabolism in damaged brain regions following transient cerebral ischemia.
Ischemic Stroke
Heterologous expression and purification of kynurenine-3-monooxygenase from Pseudomonas fluorescens strain 17400.
kynurenine 3-monooxygenase deficiency
Kynurenine plays an immunosuppressive role in 2,4,6-trinitrobenzene sulfate-induced colitis in mice.
Peripheral kynurenine-3-monooxygenase deficiency as a potential risk factor for metabolic syndrome in schizophrenia patients.
Leiomyomatosis
Germline deletions of EXO1 do not cause colorectal tumors and lesions which are null for EXO1 do not have microsatellite instability.
Liver Neoplasms
Identifying Key Genes of Liver Cancer by Networking of Multiple Data Sets.
Malaria
Efficient population modification gene-drive rescue system in the malaria mosquito Anopheles stephensi.
Mania
Differences in kynurenine metabolism during depressive, manic, and euthymic phases of bipolar affective disorder.
The KMO allele encoding Arg(452) is associated with psychotic features in bipolar disorder type 1, and with increased CSF KYNA level and reduced KMO expression.
Melanoma
Kynurenine 3-monooxygenase (KMO), and signal transducer and activator of transcription 3 (STAT3) expression is involved in tumour proliferation and predicts poor survival in canine melanoma.
Meningitis, Bacterial
The cerebral protective effect and mechanism of action of vitamin B6 adjuvant ceftriaxone in experimental pneumococcal meningitis.
Mercury Poisoning
Chinese patent medicine as a potential source of mercury poisoning.
Chronic mercury exposure in Late Neolithic/Chalcolithic populations in Portugal from the cultural use of cinnabar.
Myocarditis
Absence of kynurenine 3-monooxygenase reduces mortality of acute viral myocarditis in mice.
Neoplasms
Exhaustion of CD4+ T-cells mediated by the Kynurenine Pathway in Melanoma.
Fish oil ameliorates sickness behavior induced by lipopolysaccharide in aged mice through the modulation of kynurenine pathway.
Fluoxetine prevents the development of depressive-like behavior in a mouse model of cancer related fatigue.
Immunomodulatory Effects of Genetic Alterations Affecting the Kynurenine Pathway.
Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).
Kynurenine 3-monooxygenase (KMO), and signal transducer and activator of transcription 3 (STAT3) expression is involved in tumour proliferation and predicts poor survival in canine melanoma.
Kynurenine 3-monooxygenase upregulates pluripotent genes through ?-catenin and promotes triple-negative breast cancer progression.
Kynurenine pathway enzyme KMO in cancer progression: A tip of the Iceberg.
Overexpression of Kynurenine 3-Monooxygenase Correlates with Cancer Malignancy and Predicts Poor Prognosis in Canine Mammary Gland Tumors.
Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple myeloma.
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond.
Tryptophan PET Imaging of the Kynurenine Pathway in Patient-Derived Xenograft Models of Glioblastoma.
Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer.
Nephritis, Interstitial
Organic anion transporter 1 and 3 contribute to traditional Chinese medicine-induced nephrotoxicity.
Nervous System Diseases
Biochemistry and structural studies of kynurenine 3-monooxygenase reveal allosteric inhibition by Ro 61-8048.
Kynurenine 3-monooxygenase from Pseudomonas fluorescens: substrate-like inhibitors both stimulate flavin reduction and stabilize the flavin-peroxo intermediate yet result in the production of hydrogen peroxide.
Neuralgia
Pharmacological Inhibition of Indoleamine 2,3-Dioxygenase-2 and Kynurenine 3-Monooxygenase, Enzymes of the Kynurenine Pathway, Significantly Diminishes Neuropathic Pain in a Rat Model.
Pharmacological kynurenine 3-monooxygenase enzyme inhibition significantly reduces neuropathic pain in a rat model.
The Role of the Kynurenine Signaling Pathway in Different Chronic Pain Conditions and Potential Use of Therapeutic Agents.
Upregulation of neuronal kynurenine 3-monooxygenase mediates depression-like behavior in a mouse model of neuropathic pain.
Neurodegenerative Diseases
A brain-permeable inhibitor of the neurodegenerative disease target kynurenine 3-monooxygenase prevents accumulation of neurotoxic metabolites.
A fluorescence polarization binding assay to identify inhibitors of flavin-dependent monooxygenases.
A magnetic bead-based ligand binding assay to facilitate human kynurenine 3-monooxygenase drug discovery.
Advantages of brain penetrating inhibitors of kynurenine-3-monooxygenase for treatment of neurodegenerative diseases.
Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway.
Development of a Rapid Fluorescence-Based High-Throughput Screening Assay to Identify Novel Kynurenine 3-Monooxygenase Inhibitor Scaffolds.
Development of LC/MS/MS, High-Throughput Enzymatic and Cellular Assays for the Characterization of Compounds That Inhibit Kynurenine Monooxygenase (KMO).
Dual Role of the Carboxyl-terminal Region of Pig Liver L-Kynurenine 3-Monooxygenase: Mitochondrial Targeting Signal and Enzymatic Activity.
First molecular modeling report on novel arylpyrimidine kynurenine monooxygenase inhibitors through multi-QSAR analysis against Huntington's disease: A proposal to chemists!
Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).
Kynurenine 3-monooxygenase (KMO), and signal transducer and activator of transcription 3 (STAT3) expression is involved in tumour proliferation and predicts poor survival in canine melanoma.
Kynurenine Monooxygenase (KMO) Inhibitors for the Treatment of Acute Pancreatitis and Neurodegenerative Disorders.
Protective role of cinnabar and realgar in Hua-Feng-Dan against LPS plus rotenone-induced neurotoxicity and disturbance of gut microbiota in rats.
Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenase.
Structural Basis for Inhibitor-Induced Hydrogen Peroxide Production by Kynurenine 3-Monooxygenase.
Structural basis of kynurenine 3-monooxygenase inhibition.
Substrate and inhibitor specificity of kynurenine monooxygenase from Cytophaga hutchinsonii.
The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease.
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond.
Obesity
Erratum: The kynurenine pathway is activated in human obesity and shifted toward kynurenine monooxygenase activation.
Peripheral kynurenine-3-monooxygenase deficiency as a potential risk factor for metabolic syndrome in schizophrenia patients.
The kynurenine pathway is activated in human obesity and shifted toward kynurenine monooxygenase activation.
Oral Ulcer
[Detection of Cinnabars in Mongolian Medicines Using Raman Spectroscopy].
Ototoxicity
Ototoxicity induced by cinnabar (a naturally occurring HgS) in mice through oxidative stress and down-regulated Na(+)/K(+)-ATPase activities.
Pancreatitis
Development of a Series of Kynurenine 3-Monooxygenase Inhibitors Leading to a Clinical Candidate for the Treatment of Acute Pancreatitis.
Increased levels of 3-hydroxykynurenine parallel disease severity in human acute pancreatitis.
Kynurenine Monooxygenase (KMO) Inhibitors for the Treatment of Acute Pancreatitis and Neurodegenerative Disorders.
Pancreatitis: KMO inhibitor for multi-organ failure in experimental acute pancreatitis.
The discovery of potent and selective kynurenine 3-monooxygenase inhibitors for the treatment of acute pancreatitis.
Parkinson Disease
A novel role for kynurenine 3-monooxygenase in mitochondrial dynamics.
Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in Parkinsonian monkeys.
Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites.
Pneumoconiosis
[On the problem of the combined effect of cinnabar and mercury vapor on the development of pneumoconiosis in experimental animals]
Proteinuria
Loss of Kynurenine 3-Mono-oxygenase Causes Proteinuria.
Reperfusion Injury
Kynurenine 3-monooxygenase is a critical regulator of renal ischemia-reperfusion injury.
Realgar and cinnabar are essential components contributing to neuroprotection of Angong Niuhuang Wan with no hepatorenal toxicity in transient ischemic brain injury.
Sepsis
Is sepsis-induced apoptosis associated with macrophage dysfunction?
Sexually Transmitted Diseases
[Mercury--a major agent in the history of medicine and alchemy]
Spasm
A Gift from the Buddhist Monastery: The Role of Buddhist Medical Practices in the Assimilation of the Opium Poppy in Chinese Medicine during the Song Dynasty (960-1279).
Stroke
Kynurenine 3-monooxygenase from Pseudomonas fluorescens: substrate-like inhibitors both stimulate flavin reduction and stabilize the flavin-peroxo intermediate yet result in the production of hydrogen peroxide.
Trachoma
[Mercury--a major agent in the history of medicine and alchemy]
Triple Negative Breast Neoplasms
Kynurenine 3-monooxygenase upregulates pluripotent genes through ?-catenin and promotes triple-negative breast cancer progression.
Virus Diseases
Absence of kynurenine 3-monooxygenase reduces mortality of acute viral myocarditis in mice.
Kynurenine 3-Monooxygenase Inhibition during Acute Simian Immunodeficiency Virus Infection Lowers PD-1 Expression and Improves Post-Combination Antiretroviral Therapy CD4+ T Cell Counts and Body Weight.
Yellow Fever
Analysis of the wild-type and mutant genes encoding the enzyme kynurenine monooxygenase of the yellow fever mosquito, Aedes aegypti.